Navigation Links
Enobia Raises US$50M from Current Investors in Series C Financing
Date:8/10/2009

MONTREAL, Aug. 10 /PRNewswire/ -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, today announced that it raised US$50 million from its current investors in a Series C financing. The proceeds will be used primarily to fund the ongoing development program for ENB-0040, Enobia's enzyme replacement therapy (ERT) for hypophosphatasia (HPP), a rare and potentially deadly genetic bone disorder for which there is no currently approved therapy. In addition, a portion of the proceeds will be used to fund an unspecified development program.

Participants in the financing include OrbiMed Advisors LLC ("OrbiMed") of New York, CTI Life Sciences Fund of Montreal ("CTI"), the Fonds de Solidarite FTQ, Desjardins Venture Capital and Lothian Partners. All previously participated in the CDN$40.1M Series B financing in August 2007.

"Enobia and our collaborators have been enormously pleased by the early clinical results in infants with severe hypophosphatasia. We are fortunate to have the ongoing support of knowledgeable investors helping the Company to advance the ENB-0040 development program," said Robert Heft, PhD, President and CEO of Enobia. "This new round of financing will provide the Company with sufficient capital to fund our activities through the first half of 2011 and to reach important clinical and manufacturing milestones."

"This financing underscores our enthusiasm for the potential of ENB-0040 in patients with HPP," said Jonathan Silverstein, Enobia Chairman and General Partner of OrbiMed. "We're pleased to build on our existing relationship with this team of scientists and management who are dedicated to finding treatments for this and other devastating rare bone disorders."

Six month safety and efficacy results of Enobia's Phase I/II study of ENB-0040 in infants with the severe form of HPP will be pr
'/>"/>

SOURCE Enobia Pharma
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
2. Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
3. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
4. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Enobia Pharma Raises $40.1 Million Series B Financing
7. TSH Testing Raises Awareness of Importance of Thyroid Health
8. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
9. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
10. Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
11. Americans United for Life: Obamas Disbanding Bioethics Council Raises Troubling Questions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
(Date:5/23/2013)... Canada (PRWEB) May 23, 2013 ... it is critical to adhere to principles of ... (HSP). , Esteemed speaker Dr. Jeremy Lim, Fellow, ... audience: , ,     Understand the International ... Practice (GCP) and additional regulations for the conduction ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Bed bugs already ... the pests is still ongoing, a report from kmov.com suggested ... for the bed bug treatment. Meanwhile, to be of help, ... from the costly bed bug exterminator service. , ... that AHA has so far spent $35,000 for ...
Breaking Biology Technology:Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2Bed Bug Exterminator Service Could Cost AHA $250K, My Cleaning Products Gives Tips How to Save Apartments from Costly Bed Bug Treatment 2
... Dec. 11 Myngle,( http://www.myngle.com ), the global ... ICT company at the Europe Unlimited,s European Venture ... EVS is a showcase for ... and new energy entrepreneurs from all over Europe ...
... Inc. (Nasdaq: PBIO ) ("PBI" or the ... have entered into a strategic marketing, distribution, and technology ... companies will: (1) share market data, customer leads, technology ... industry trade shows beginning in 2009; (3) license Omni ...
... HAMBURG, Germany, December 11 Olympus has further,cemented its ... invasive surgery,by signing an exclusive and immediate deal to ... ASC is the sole global,provider of ports for state-of-the-art ... patient,s navel. Olympus is now the exclusive,distributor for the ...
Cached Biology Technology:Myngle Best ICT Company at the European Ventures Summit 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 3Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 4Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 5Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts 2
(Date:5/22/2013)... to genetic engineering drastically reduces the time and ... the workhorses of biotechnology, scientists are reporting. Published ... the method paves the way for more rapid ... cleanup and other activities. , Keith Shearwin and ... of the genetic material DNA into a bacterium,s ...
(Date:5/22/2013)... Irvine, Calif., May 22, 2013 Early screening for ... personal pregnancy testing is for women, thanks to UC ... the American Chemical Society . , After more than ... a way to clearly identify clinically usable markers for ... be detected far sooner, with greater accuracy and at ...
(Date:5/21/2013)... increasingly being considered in the management of natural ... that can help them recognize and respond to ... their lives. , Place-Based Conservation: Perspectives from ... the Pacific Northwest Research Station,s Linda Kruger, can ... The book is published by Springer Verlag and ...
Breaking Biology News(10 mins):UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... at the University of Pennsylvania School of Medicine have ... a vaccine used to study HIV in macaque monkeys ... (SHIV) than an unmodified vaccine. This multi-year study found ... boosts the effects of a vaccine derived from the ...
... of lead in children,s blood -- amounts well below ... IQ scores, finds a new six-year Cornell study., The ... function in children whose blood-lead levels (BLLs) were below ... of 10 micrograms per deciliter (mcg/dl) -- about 100 ...
... --- Driving down a country road at night your cars ... doesnt move. Depending on your speed and other conditions, chances ... do, its because you are in what is fittingly defined ... published online Nov. 13 by the journal PLoS Biology. ...
Cached Biology News:Penn researchers find monkeys able to fend off AIDS-like symptoms with enhanced HIV vaccine 2Even minute levels of lead cause brain damage in children 2Northwestern study looks at sensing, movement and behavior 2Northwestern study looks at sensing, movement and behavior 3
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
Biology Products: